sandy bartlett phd pharmd bcps associate professor
play

Sandy Bartlett, PhD, PharmD, BCPS Associate Professor | Department of Pharmacy Practice Conflict of Interest I have no actual or potential conflict of interest in relation to this program to disclose. Slide 2 Learning Objectives

0 downloads 8 Views 1,11 MB Size Report
  1. Sandy Bartlett, PhD, PharmD, BCPS Associate Professor | Department of Pharmacy Practice

  2. Conflict of Interest  I have no actual or potential conflict of interest in relation to this program to disclose. Slide 2

  3. Learning Objectives  Identify three molecular entities that are currently in development for reversal of NOACs  Compare the drug design strategy for each of these new pipeline reversal agents that are currently in clinical trials  Evaluate how these potential new agents may be incorporated into a treatment strategy for significant bleeding related to NOAC use based on patient specific information Slide 3

  4. New Oral Anticoagulants (NOACs) BACKGROUND Slide 4

  5. Dabigatran (Boehringer Ingelheim)  FDA approvals  NVAF  October 2010  DVT/PE Treatment  April 2014 Structure adapted by S Bartlett from Blommel ML and Blommel AL, AJHP, 2011;68:1506-19. Slide 5

  6. Rivaroxaban (Janssen)  FDA approvals  NVAF  November 2011  DVT/PE  November 2012  Knee/Hip VTE  July 2011 Slide 6 Adapted by S Bartlett from Perzborn E et al., Nature Reviews Drug Discovery, 2011;10:61 – 75. –

  7. Apixaban (Bristol-Myers Squibb)  FDA approvals  NVAF  December 2012  DVT/PE Treatment  August 2014  Knee/Hip VTE Prevention  March 2014 Slide 7 Adapted by S Bartlett from Perzborn E et al., Nature Reviews Drug Discovery, 2011;10:61 – 75. –

  8. Edoxaban (Daiichi Sankyo)  FDA approvals  NVAF  January 2015  DVT/PE Treatment  January 2015 Slide 8 Adapted by S Bartlett from Perzborn E et al., Nature Reviews Drug Discovery, 2011;10:61 – 75. –

  9. NOAC Targets Apixa xaban ban Intri trinsic sic Extrinsic rinsic Edoxa xaban ban IXa VII IIa Pathway Pathway Rivaroxa xaban ban TF TF X Xa Xa X Va IIa IIa Dabig igatr tran an II II I Ia Ia XIIIa IIa Clot Adapted by S Bartlett from Sabir I et al., Nat Rev Cardiol, Drug Discovery, 2014;11:290 – 303.

  10. No Specific NOAC Antidote Available  Patient taking NOACs may still experience  Major bleeding complications  Similar or lower bleeding rates than with warfarin  Trauma injuries  Require urgent / emergent surgery Majeed A and Schulman S. Bleeding and Antidotes in New Oral Anticoagulants, Best Pract Res Clin Haematol , 2013;26:191-202. Slide 10

  11. Learning Objectives  Identify three molecular entities that are currently in development for reversal of new oral anticoagulant (NOAC) agent(s)  Compare the drug design strategy for each of these new pipeline reversal agents that are currently in clinical trials  Evaluate how these potential new agents may be incorporated into a treatment strategy for significant bleeding related to NOAC use based on patient specific information Slide 11

  12. Pipeline Reversal Agents  Idarucizumab (Boehringer Ingelheim)  Andexanet alfa (Portola Pharmaceuticals)  Aripazine (Perosphere) Slide 12

  13. Learning Objectives  Identify three molecular entities that are currently in development for reversal of new oral anticoagulant (NOAC) agent(s)  Compare the drug design strategy for each of these new pipeline reversal agents that are currently in clinical trials  Evaluate how these potential new agents may be incorporated into a treatment strategy for significant bleeding related to NOAC use based on patient specific information Slide 13

  14. Pipeline Agents for NOAC Reversal IDARUCIZUMAB Slide 14

  15. Idarucizumab  Humanized mAb fragment against dabigatran  Target  Dabigatran http://www.rcsb.org/pdb/explore/explore.do?structureId=4YGV Schiele F, van Ryn J, Litzenburger T, Ritter M et al., Structure-guided Residence Time Optimization of a Dabigatran Reversal Agent, MAbs, 2015;7:871-880. Slide 15

  16. Tight Binding Affinity for Dabigatran Ligand – Target Binding K D (nM) Dabigatran - Thrombin 0.7 Dabigatran - Idarucizumab 0.002  Binding affinity is 350-fold higher for idarucizumab over thrombin Pollack Jr CV, Reilly PA, Bernstein R, Dubiel R et al., Design and Rationale for RE-VERSE AD: A Phase 3 Study of Idarucizumab, a Specific Reversal Slide 16 Agent for Dabigatran, Thromb Haemost, 2015;114:198-205.

  17. Dabigatran Binding to Idarucizumab Schiele F, van Ryn J, Canada K, Newsome C et al., A Specific Antidote for Dabigatran: Functional and Structural Characterization, Blood, 2013;121:3554- Slide 17 3526.

  18. RE-VERSE AD  Interim Results  REVER Sal E ffects of Idarucizumab in Patients on A ctive D abigatran  Phase 3 multicenter, prospective cohort study  Group A: Uncontrollable or life-threatening bleeding (n=51)  Group B: Urgent surgery or intervention (n=39)  Intervention  Patient received idarucizumab 5 g IV  Two 50 mL bolus infusions  15 minutes apart Pollack Jr CV, Reilly PA, Eikelboom J, Glund S et al., Idarucizumab for Dabigatran Reversal, N Engl J Med, 2015;373:511-520. Slide 18

  19. RE-VERSE AD Interim Results  Primary end point  Maximal reversal of dabigatran based on laboratory assessment within 4 h after idarucizumab administration  Dilute thrombin time or ecarin clotting time  Results  Median maximum reversal = 100%  68/90 patients (75%) had an elevated dilute thrombin time at baseline  81/90 patients (90%) had an elevated ecarin clotting time at baseline Pollack Jr CV, Reilly PA, Eikelboom J, Glund S et al., Idarucizumab for Dabigatran Reversal, N Engl J Med, 2015;373:511-520. Slide 19

  20. Successful Reversal in Bleeding Patients Pollack Jr CV, Reilly PA, Eikelboom J, Glund S et al., Idarucizumab for Dabigatran Reversal, N Engl J Med, 2015;373:511-520. Slide 20

  21. Successful Reversal for Urgent Procedures Pollack Jr CV, Reilly PA, Eikelboom J, Glund S et al., Idarucizumab for Dabigatran Reversal, N Engl J Med, 2015;373:511-520. Slide 21

  22. Pipeline Agents for NOAC Reversal ANDEXANET ALFA Slide 22

  23. Andexanet alfa  Modified recombinant Factor X protein expressed in CHO cells  Targets  Factor Xa inhibitors  Rivaroxaban, Apixaban, Edoxaban http://www.portola.com/clinical- development/andexanet-alfa-prt4445-fxa- inhibitor-antidote/  LMWH & Fondaparinux Schiele F, van Ryn J, Litzenburger T, Ritter M et al., Structure-guided Residence Time Optimization of a Dabigatran Reversal Agent, MAbs, 2015;7:871-880. Slide 23

  24. Andexanet Protein Design  Modifications to Factor Xa  Removal of the activation peptide and replace with RKR to form the linker that connects the light chain to the heavy chain Adapted by S Bartlett from Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ et al., A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Slide 24 Inhibitors of Coagulation Factor Xa, Nat Med, 2013;19:446-451.

  25. Andexanet Protein Design  Modifications to Factor Xa to prevent procoagulant activity  Mutation of Ser  Ala in active site Adapted by S Bartlett from Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ et al., A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Slide 25 Inhibitors of Coagulation Factor Xa, Nat Med, 2013;19:446-451.

  26. Andexanet Protein Design  Modifications to Factor Xa to prevent anticoagulant activity  Removal of ɣ -carboxyglutamic acid membrane binding domain Adapted by S Bartlett from Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ et al., A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Slide 26 Inhibitors of Coagulation Factor Xa, Nat Med, 2013;19:446-451.

  27. Decoy Mechanism for NOACs Andexanet Factor Xa Ligand Affinity  K D (nM) K D (nM) 5.8-fold  Apixaban 0.58 0.100 3.8-fold  Rivaroxaban 1.53 0.400  Decoy binds NOACs and reverses Factor Xa inhibition and restores ability to generate thrombin for hemostasis Yeh CH, Fredenburgh JC, Weitz JL. The Real Decoy: An Antidote for Factor Xa-directed Anticoagulants, Circ Res, 2013;113:954-957; Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ et al., A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Inhibitors of Coagulation Factor Xa, Nat Slide 27 Med, 2013;19:446-451.

  28. Andexanet Reverses Rivaroxaban in Rabbit Liver Laceration Model  75 mg andexanet IV reduces blood loss by > 85% in rivaroxaban treated rabbits (1 mg/kg) Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ et al., A Specific Antidote for Reversal of Anticoagulation by Direct and Indirect Inhibitors of Coagulation Slide 28 Factor Xa, Nat Med, 2013;19:446-451.

  29. Andexanet Infusion Achieved Sustained Reversal of Apixaban Anticoagulation http://www.sec.gov/Archives/edgar/data/1269021/000156459014000472/ptla-10k_20131231.htm  Phase 2 placebo controlled trial in healthy volunteers  5 mg PO Apixaban BID x 5 days Adapted from Crowther M, Lu G, Conley P, Hollenbach S et al., Sustained Reversal of Apixaban Anticoagulation with Andexanet alfa Using a Bolus Plus Infusion Regimen in a Phase 2 Placebo Controlled Trial, Eur Heart J, 2014;35:137 (Abstract). Slide 29

  30. Pipeline Agents for NOAC Reversal ARIPAZINE (PER977) Slide 30

  31. Aripazine  Small molecule inhibitor  Targets  UFH  LMWH & Fondaparinux National Center for Biotechnology Information. PubChem Substance  Factor Xa inhibitors Database; SID=249807675, https://pubchem.ncbi.nlm.nih.gov/substance/249807675 (accessed Aug. 31, 2015).  Rivaroxaban, Apixaban, Edoxaban  Thrombin inhibitors  Dabigatran Slide 31

Recommend Documents


transition to pharm d model
Transition to Pharm.D. Model

Transition to Pharm.D. Model Presenters: Shaun E. Gleason, PharmD, MGS

pharmacogenomic pgx data practical
Pharmacogenomic (PGx) Data: Practical

Improving Medication Use With Pharmacogenomic (PGx) Data: Practical

hiv management update 2015
HIV Management Update 2015 Larry

9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS

rotations
Rotations Angharad Ratliff, PharmD,

Creating Excellent Student Rotations Angharad Ratliff, PharmD, BCPS,BCCCP

studies equigen in
STUDIES (EQUIGEN) IN PATIENTS WITH

MULTIPLE AND SINGLE DOSE STUDIES (EQUIGEN) IN PATIENTS WITH EPILEPSY Timothy

infectious considerations before during and after medical
Infectious Considerations Before During

Infectious Considerations Before During and After Medical Mission Trips Elias

diabetes
Diabetes Oh My! Devices Workshop

1/17/2018 Pumps & Sensors & Meters, Diabetes Oh My! Devices

applying the intricacies of the new hypertension and
Applying the Intricacies of the New

Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your

naloxone counseling for harm reduction patient engagement
Naloxone Counseling for Harm Reduction

Naloxone Counseling for Harm Reduction & Patient Engagement Lucas G. Hill,

alemtuzumab
Alemtuzumab Indicated for relapsing

2/3/2018 ALEMTUZUMAB ASSOCIATED LISTERIA MONOCYTOGENES MENINGITIS DURING THE

atrial fibrillation reducing the risk of stroke
Atrial fibrillation Reducing The Risk

Atrial fibrillation Reducing The Risk of Stroke Bjrn Fredriksson Arrhythmia

expanded mandate medicines patent pool for essential
EXPANDED MANDATE: MEDICINES PATENT

EXPANDED MANDATE: MEDICINES PATENT POOL FOR ESSENTIAL MEDICINES KEY FINDINGS

drug spending of healthcare spending
Drug Spending % of Healthcare Spending

Drug Spending % of Healthcare Spending DRUG SPENDING % OF HEALTHCARE SPENDING

showcasing
Showcasing health innovation Dr Samus

Showcasing health innovation Dr Samus ONeill Chair AHSN Network, CEO AHSN

updates in thrombosis
Updates in Thrombosis Dr. Ali Y.

Updates in Thrombosis Dr. Ali Y. Al-Muhaini MBBch FRCP(C) Chairman of the

anticoagulation
Anticoagulation Laurel Newman Quality

Anticoagulation Laurel Newman Quality implementation Manager Primary Care

updates from the pharmacovigilance and special access
Updates from the Pharmacovigilance and

Updates from the Pharmacovigilance and Special Access Branch Dr Grant Pegg

effectiveness and safety of
Effectiveness and safety of direct oral

Pharmacologie mdicale Pharmacologie mdicale Pharmaco-pidmiologie Bordeaux

emergency treatment of ischemic stroke
Emergency Treatment of Ischemic Stroke

Emergency Treatment of Ischemic Stroke JEFFREY BOYLE, M.D., PHD CLINICAL

medicine
Medicine Hamid Afshar, MD Baylor

Innovative Technologies in Cardiovascular Medicine Hamid Afshar, MD Baylor

geriatrics
GERIATRICS HOW IT MIGHT AFFECT YOUR

GERIATRICS HOW IT MIGHT AFFECT YOUR PRACTICE Natalie D. Garry, RN, BSN, MSN,

remote damage control resuscitation an overview for
Remote Damage Control Resuscitation:

Remote Damage Control Resuscitation: An Overview for Medical Directors and